Page 152 - Cascade_Biocatalysis_Integrating_Stereoselective_and_Environmentally_Friendly_Reactions

128 5 Multi-Enzyme Systems and Cascade Reactions Involving Cytochrome P450 Monooxygenases

53. Lewis, D.F. (2003) P450 structures and reactions in human liver micro-
oxidative metabolism of xenobiotics. somes. Drug Metab. Dispos., 28 (11),
Pharmacogenomics, 4 (4), 387–395. 1284–1290.
54. Shen, L., Fitzloff, J.F., and Cook, C.S. 62. Osborne, C.K. (1998) Tamoxifen in the
(2004) Differential enantioselectiv- treatment of breast cancer. N. Engl. J.
ity and product-dependent activation Med., 339 (22), 1609–1618.
and inhibition in metabolism of vera- 63. Fisher, B., Costantino, J.P.,
pamil by human CYP3As. Drug Metab. Wickerham, D.L., Redmond, C.K.,
Dispos., 32 (2), 186–196. Kavanah, M., Cronin, W.M., Vogel,
55. Lindberg, P., Nordberg, P., Alminger, V., Robidoux, A., Dimitrov, N., Atkins,
T., Brandstrom, A., and Wallmark, J., Daly, M., Wieand, S., Tan-Chiu,
B. (1986) The mechanism of action E., Ford, L., and Wolmark, N. (1998)
of the gastric acid secretion inhibitor Tamoxifen for prevention of breast
omeprazole. J. Med. Chem., 29 (8), cancer: report of the National Surgical
1327–1329. Adjuvant Breast and Bowel Project P-1
Study. J. Natl. Cancer Inst., 90 (18),
56. Andersson, T., Hassan-Alin, M.,
1371–1388.
Hasselgren, G., Rohss, K., and Weidolf,
64. Borgna, J.L. and Rochefort, H. (1981)
L. (2001) Pharmacokinetic studies
Hydroxylated metabolites of tamoxifen
with esomeprazole, the (S)-isomer of
omeprazole. Clin. Pharmacokinet., 40 are formed in vivo and bound to estro-
(6), 411–426. gen receptor in target tissues. J. Biol.
57. Davydov, D.R. (2011) Microsomal Chem., 256 (2), 859–868.
65. Jordan, V.C. (1982) Metabolites of
monooxygenase as a multienzyme sys-
tamoxifen in animals and man:
tem: the role of P450-P450 interactions.
identification, pharmacology, and
Expert Opin. Drug Metab. Toxicol., 7 (5),
significance. Breast Cancer Res. Treat., 2
543–558.
(2), 123–138.
58. Hashizume, T., Mise, M., Terauchi, 66. Desta, Z., Ward, B.A., Soukhova,
Y., Fujii, L.O.T., Miyazaki, H., and N.V., and Flockhart, D.A. (2004) Com-
Inaba, T. (1998) N-Dealkylation and
prehensive evaluation of tamoxifen
hydroxylation of ebastine by human
sequential biotransformation by the
liver cytochrome P450. Drug Metab.
human cytochrome P450 system in
Dispos., 26 (6), 566–571.
vitro: prominent roles for CYP3A and
59. Hashizume, T., Imaoka, S., Mise, M.,
CYP2D6. J. Pharmacol. Exp. Ther., 310
Terauchi, Y., Fujii, T., Miyazaki, H.,
(3), 1062–1075.
Kamataki, T., and Funae, Y. (2002)
67. Jones, G., Strugnell, S.A., and DeLuca,
Involvement of CYP2J2 and CYP4F12
H.F. (1998) Current understanding of
in the metabolism of ebastine in
the molecular actions of vitamin D.
human intestinal microsomes. J. Phar-
Physiol. Rev., 78 (4), 1193–1231.
macol. Exp. Ther., 300 (1), 298–304. 68. Sawada, N., Sakaki, T., Ohta, M.,
60. Liu, K.H., Kim, M.G., Lee, D.J., Yoon, and Inouye, K. (2000) Metabolism of
Y.J., Kim, M.J., Shon, J.H., Choi, vitamin D(3) by human CYP27A1.
C.S., Choi, Y.K., Desta, Z., and Shin, Biochem. Biophys. Res. Commun., 273
J.G. (2006) Characterization of ebas- (3), 977–984.
tine, hydroxyebastine, and carebastine 69. Strushkevich, N., Usanov, S.A.,
metabolism by human liver micro- Plotnikov, A.N., Jones, G., and Park,
somes and expressed cytochrome P450 H.W. (2008) Structural analysis of
enzymes: major roles for CYP2J2 and CYP2R1 in complex with vitamin D3.
CYP3A. Drug Metab. Dispos., 34 (11), J. Mol. Biol., 380 (1), 95–106.
1793–1797. 70. Yamamoto, K., Uchida, E., Urushino,
61. Thijssen, H.H., Flinois, J.P., and N., Sakaki, T., Kagawa, N., Sawada,
Beaune, P.H. (2000) Cytochrome N., Kamakura, M., Kato, S., Inouye,
P4502C9 is the principal catalyst of K., and Yamada, S. (2005) Identifi-
racemic acenocoumarol hydroxylation cation of the amino acid residue of